Robert_Bradway

Amgen promotes Robert Bradway to president

pharmafile | April 28, 2010 | Appointment | Manufacturing and Production, Sales and Marketing Amgen, appointment, manufacturing and production, sales and marketing 

Robert Bradway has been appointed president and chief operating officer at US biotech Amgen.

Bradway, currently executive VP and chief financial officer, will assume his new role on 11 May, when he will take responsibility for Amgen’s global commercial operations.

His remit will also include overseeing strategy and corporate development, information technology, manufacturing operations and global government affairs and compliance.

Bradway first joined Amgen in 2006 as VP, operations strategy, prior to which he was a managing director at Morgan Stanley in London where he had responsibility for the firm’s banking department and corporate finance activities in Europe.

He joined Morgan Stanley in New York as a health care industry investment banker in 1985 and moved to London in 1990 where he served as head of the firm’s international health care investment banking activities until assuming broader corporate finance management responsibilities.

Meanwhile, Amgen’s executive vice president of global commercial operations George Morrow will retire 31 January 2011.

Morrow became executive vice president of worldwide sales and marketing for Amgen in January 2001, and executive vice president, global commercial operations in April 2003.

Prior to Amgen, he was president and chief executive of Glaxo Wellcome Inc, the US subsidiary of what is now GlaxoSmithKline.

Finally, from 11 May Michael Kelly, Amgen’s vice president of finance and chief accounting officer, will serve as acting chief financial officer. He joined Amgen in 2003 and has served as chief accounting officer since 2005.

Related Content

Amgen opens new biomanufacturing facility in Ohio, US

Amgen has announced that it has opened a new manufacturing site in Central Ohio, US. …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

Amgen flag

Amgen stomach cancer drug awarded Breakthrough Therapy Designation

Amgen’s investigational therapy, bemarituzumab, for certain types of stomach and esophagus cancer, has been granted …

Latest content